Patents by Inventor Alexey Ishchenko

Alexey Ishchenko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
    Publication number: 20220315575
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: July 17, 2020
    Publication date: October 6, 2022
    Inventors: Andrew P. Crew, Michael Berlin, Hanqing Dong, Alexey Ishchenko, Angela M. Cacace, Julian T. Chandler
  • Tau-protein targeting PROTACs and associated methods of use
    Patent number: 11458123
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: October 4, 2022
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Michael Berlin, Hanqing Dong, Alexey Ishchenko
  • EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE
    Publication number: 20180193470
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand which binds to an E3 ubiquitin ligase and on the other end a moiety which binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effectuate ubiquitination, and therefore, degradation (and inhibition) of the target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: December 22, 2017
    Publication date: July 12, 2018
    Inventors: Andrew P. Crew, Kurt Zimmermann, Jing Wang, Michael Berlin, Hanqing Dong, Alexey Ishchenko, Yimin Qian, Craig M. Crews, Saul Jaime-Figueroa, George Burslem
  • TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
    Publication number: 20180125821
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: November 1, 2017
    Publication date: May 10, 2018
    Inventors: Andrew P. Crew, Michael Berlin, John J. Flanagan, Hanqing Dong, Alexey Ishchenko
  • Heteroaryl Btk inhibitors
    Patent number: 9029359
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 12, 2015
    Assignees: Biogen Idec MA, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Minna Bui, Patrick Conlon, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Alexey Ishchenko, Tracy J. Jenkins, Gnanasambandam Kumaravel, Doug Marcotte, Noel Powell, Daniel Scott, Art Taveras, Deping Wang, Min Zhong
  • HETEROARYL BTK INHIBITORS
    Publication number: 20120157442
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 3, 2010
    Publication date: June 21, 2012
    Applicants: SUNESIS PHARMACEUTICALS, INC., BIOGEN IDEC MA INC.
    Inventors: Minna Bui, Patrick Conlon, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Alexey Ishchenko, Tracy J. Jenkins, Gnanasambandam Kumaravel, Doug Marcotte, Noel Powell, Daniel Scott, Art Taveras, Deping Wang, Min Zhong
  • HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
    Publication number: 20120040951
    Abstract: The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Application
    Filed: December 30, 2009
    Publication date: February 16, 2012
    Inventors: Claudio Chuaqui, Jennifer Cossrow, James Dowling, Bing Guan, Michael Hoemann, Alexey Ishchenko, John Howard Jones, Lori Kabigting, Gnanasambandam Kumaravel, Hairuo Peng, Noel Powell, Brian Raimundo, Hiroko Tanaka, Kurt van Vloten, Jeffrey Vessels, Zhili Xin
  • Heterocyclic compounds useful as RAF kinase inhibitors
    Patent number: 7968536
    Abstract: The present invention provides compounds useful as inhibitors of protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: June 28, 2011
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Jennifer Cossrow, Bing Guan, Alexey Ishchenko, John Howard Jones, Gnanasambandam Kumaravel, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Heterocyclic Compounds Useful as RAF Kinase Inhibitors
    Publication number: 20090005359
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Application
    Filed: June 30, 2008
    Publication date: January 1, 2009
    Applicant: Sunesis Pharmaceuticals, Inc
    Inventors: Jennifer Cossrow, Bing Guan, Alexey Ishchenko, John Howard Jones, Gnanasambandam Kumaravel, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin